DexCom (NASDAQ:DXCM) Rating Lowered to Hold at StockNews.com

DexCom (NASDAQ:DXCM) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

A number of other research firms have also recently issued reports on DXCM. UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Raymond James raised their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, Citigroup raised their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $141.40.

DexCom Stock Up 1.9 %

Shares of DXCM stock traded up $2.48 on Tuesday, reaching $134.00. 2,014,507 shares of the company were exchanged, compared to its average volume of 2,958,850. The company has a market cap of $51.66 billion, a price-to-earnings ratio of 102.29, a PEG ratio of 2.25 and a beta of 1.20. The company has a 50-day moving average of $130.15 and a 200-day moving average of $117.74. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business’s revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 EPS. Analysts anticipate that DexCom will post 1.76 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. In the last 90 days, insiders sold 189,375 shares of company stock worth $25,530,859. Insiders own 0.41% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several large investors have recently modified their holdings of DXCM. Capital World Investors increased its stake in shares of DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Norges Bank purchased a new position in DexCom in the 4th quarter valued at approximately $540,178,000. Artisan Partners Limited Partnership grew its stake in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares in the last quarter. Capital Research Global Investors grew its stake in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after buying an additional 2,695,296 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new position in DexCom in the 4th quarter valued at approximately $231,773,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.